Compound
D1098 | sorafenib
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 0.96±0.09 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 1.23 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 2.25±0.63 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 0.5 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | EC20 | 36 |
| RESPIRATION | 283.4 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | decrease | EC20 | 36 |
| RESPIRATION | ND | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | Negative | EC20 | 36 |
| SWELLING | ND | 30 mins | mouse | liver mitochondria | swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling ) | Negative | EC20 | 36 |
| Target | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| NADH:ubiquinone reductase | 283.4 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | inhibit | EC20 | 36 |
| Succinate dehydrogenase | ND | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | Negative | EC20 | 36 |
| Cytochrome c | > 400 µM | 30 mins | mouse | liver mitochondria | Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline) | release | EC20 | 36 |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Danger |
Aggregated GHS information provided by 2 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H351 (50%): Suspected of causing cancer [Warning Carcinogenicity] H360 (50%): May damage fertility or the unborn child [Danger Reproductive toxicity] H361 (50%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] H362 (50%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation] H372 (50%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] H402 (50%): Harmful to aquatic life [Hazardous to the aquatic environment, acute hazard] H410 (50%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P260, P263, P264, P270, P273, P281, P308+P313, P314, P391, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| 100012-18-8 | 15216-EP2272827A1 | 15216-EP2298778A1 |
| 15216-EP2311840A1 | 15216-EP2316832A1 | 15216-EP2316833A1 |
| 1uwh | 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl- | 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- |
| 284461-73-0 | 3gcs | 3heg |
| 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide | 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide | 4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N-METHYLPICOLINAMIDE |
| 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido) phenoxy)-N-methylpicolinamide | 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido)phenoxy)-N-methylpicolinamide | 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate |
| 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide | 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide | 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)- N-methylpyridine-2-carboxamide |
| 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-picolinamide;tosylic acid | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide |
| 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide | 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide | 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; |
| 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE | 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-N-methylpyridine-2-carboxamide | 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methyl-pyridine-2-carboxamide |
| 461S730 | 4asd | 9ZOQ3TZI87 |
| AB0019677 | AB00933189-05 | AB00933189-06 |
| AB00933189_08 | AB1004622 | AC-1674 |
| ACN-032355 | ACT06732 | AK163019 |
| AKOS005560229 | AM20090614 | AOB87782 |
| BAY 43-9006 | BAY 43-9006 | BAY 439006 |
| BAY 439006 | BAY-43-0006 | BAY-43-9006 |
| BAY-439006 | BAY-54-9085 | BAY43-9006 |
| BAY439006 | BAY439006 | BCP01767 |
| BCPP000064 | BDBM16673 | BRD-K23984367-001-01-8 |
| CHEBI:50924 | CHEMBL1336 | CS-1590 |
| CS0056 | D08524 | DB00398 |
| DTXSID7041128 | EC 608-209-4 | EN002709 |
| EX-A2894 | FT-0650736 | GTPL5711 |
| HMS2043A18 | HMS3244A15 | HMS3244A16 |
| HMS3244B15 | HMS3656N20 | HSDB 8173 |
| HY-10201 | Hit compound, 8 | J10391 |
| K00597a | KS-0000009E | Kinome_766 |
| LS-186067 | LS-187021 | LS-187788 |
| MCULE-6112506696 | MFCD06411450 | MLDQJTXFUGDVEO-UHFFFAOYSA-N |
| N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea | N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea | N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea |
| N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea | N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea | NCGC00167488-01 |
| NCGC00167488-02 | NCGC00167488-03 | NCGC00167488-04 |
| NCGC00167488-05 | NCGC00167488-07 | NCGC00167488-14 |
| NSC-724772 | NSC-747971 | NSC747971 |
| Nexavar | Nexavar (TN) (Bayer) | Nexavar|||BAY 43-9006 |
| PB14443 | Q-201728 | Q421136 |
| QCR-65 | SB19942 | SC-19355 |
| SCHEMBL8218 | SF-0529 | SORAFENIB BASE |
| SR-00000000529 | SR-00000000529-1 | STK627350 |
| SW202562-4 | SYN1082 | Sorafenib |
| Sorafenib | Sorafenib (Nexavar) | Sorafenib (USAN/INN) |
| Sorafenib [INN] | Sorafenib [USAN:INN:BAN] | Sorafenib free base (BAY-43-9006) |
| Sorafenib, 4 | Sorafenib-d3 | Sorafinib |
| UNII-9ZOQ3TZI87 | Z89277543 | ZINC1493878 |
| cid_216239 | s7397 | sorafenibum |